High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms
Radhika Thokala(Parker Institute for Cancer Immunotherapy), Donald M. O’Rourke(University of Pennsylvania)
Cited by 37
Related Papers
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
|Neuro-Oncology|2018|314
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
|Frontiers in Oncology|2021|73